Isocitrate dehydrogenase (IDH) inhibitors market  target mutated IDH 1 and IDH 2 enzymes, which contribute to abnormal metabolism and proliferation in certain cancers, including acute myeloid leukemia, cholangiocarcinoma, and glioma. The market is expected to grow rapidly as more IDH‑mutated cancers are identified and treated with targeted therapies. Download Sample PDF: Market...